Kwality Pharmaceuticals has informed regarding the successful completion of the European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, encompassing both the General and Beta-Lactam units. The audit concluded with no major observations, reaffirming the company’s commitment to maintaining the highest international quality and compliance standards. This milestone underscores Kwality Pharma’s continuous pursuit of excellence in manufacturing and regulatory adherence. With this achievement, the company now has four EU-approved facilities -General, Beta-Lactam, Cephalosporin, and Oncology, strengthening its position as a trusted global pharmaceutical manufacturer across various Therapeutic areas and Dosage forms. The successful EU-GMP audit not only reinforces Kwality Pharma’s dedication to patient safety, quality assurance, and global compliance but also enables the company to expand its presence across regulated international markets, unlocking new opportunities for sustainable growth and strategic collaborations. 

The above information is a part of company’s filings submitted to BSE.